Directed Cortical Interneuron Differentiation via SHH Timing Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating cortical interneurons, hypothalamic neurons, and pre-optic cholinergic neurons in vitro are inefficient, and these cells are difficult to produce in sufficient quantities for therapeutic and research applications due to challenges in differentiation protocols and species-specific differences.
Innovation Solution
A method involving the use of SMAD inhibitors and Wnt antagonists in combination with SHH signaling activators to induce the differentiation of pluripotent and multipotent cells, such as human embryonic stem cells, to produce neuronal cells with specific markers of cortical interneurons, hypothalamic neurons, and pre-optic cholinergic neurons, followed by maturation conditions to enhance production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional in vivo administration of small molecules is used to treat neurological disorders, then the treatment approach is simple to implement, but the in vivo efficacy in patients is very modest
Solution Approach 1:
The patent uses small molecules (SMAD inhibitors, Wnt antagonists, SHH signaling activators) as intermediaries to induce differentiation of pluripotent stem cells into specific neuronal cell types in vitro, which are then transplanted for therapy, thereby achieving better efficacy than direct in vivo administration
2Reliability
If primary human neurons are obtained from live donors, then the cells are authentic human neurons, but they are difficult to obtain and cannot be cultured in vitro in the timeframe required to yield sufficient cell numbers
Solution Approach 1:
The patent performs preliminary differentiation of pluripotent stem cells into specific neuronal cell types in vitro using controlled signaling pathway modulation before transplantation, allowing sufficient time for expansion while maintaining cell authenticity and suitability for therapy
Solution Approach 2:
The patent changes the parameters of cell differentiation by modulating signaling pathway activities (SMAD, Wnt, SHH) to direct pluripotent stem cells toward specific neuronal lineages, enabling production of authentic human neurons in sufficient quantities
3Ease of manufacture
If existing differentiation protocols are used to generate cortical interneurons, hypothalamic neurons, and pre-optic cholinergic neurons in vitro, then the process is simpler, but the efficiency is low and sufficient cell quantities cannot be produced
Solution Approach 1:
The patent optimizes differentiation parameters by sequentially modulating SMAD, Wnt, and SHH signaling pathways to dramatically improve the efficiency of generating specific neuronal cell types from pluripotent stem cells while maintaining protocol feasibility
Solution Approach 2:
The patent segments the differentiation process into distinct stages with specific signaling pathway modulations at each stage, allowing efficient generation of specific neuronal subtypes while maintaining protocol manageability
Data Source
AI summary
Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.